Zacks Research Issues Optimistic Estimate for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a note issued to investors on Thursday, April 3rd. Zacks Research analyst R. Department now expects that the company will post earnings of $2.48 per share for the year, up from their prior estimate of $2.42. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2025 earnings at $0.69 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.80 EPS, Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $2.62 EPS and FY2027 earnings at $2.82 EPS.

TEVA has been the topic of several other reports. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $13.83 on Monday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries has a 1-year low of $12.51 and a 1-year high of $22.80. The stock has a market capitalization of $15.68 billion, a price-to-earnings ratio of -9.54, a PEG ratio of 1.44 and a beta of 0.82. The business’s fifty day moving average price is $16.52 and its 200-day moving average price is $18.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. FMR LLC lifted its position in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock valued at $1,806,910,000 after acquiring an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Ion Asset Management Ltd. boosted its stake in Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock worth $807,766,000 after purchasing an additional 409,778 shares during the period. Lingotto Investment Management LLP boosted its stake in Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after purchasing an additional 688,862 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after buying an additional 569,412 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.